Advertisement

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Peter Clark, MA, MD, FRCP: A Payer Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Apr

22

Today In Oncology

Adverse Events in Patients With Melanoma Treated With Ipilimumab Results of a Toxicity Monitoring Program

Risk of Leukemia in Pediatric Patients With Down Syndrome

Anesthesiologist Volume and Adverse Short-Term Outcomes After Complex Surgery for Gastrointestinal Cancer

Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response Rate for Patients With Resectable NSCLC

Copanlisib Rituximab Extends Progression-Free Survival vs Rituximab Placebo in Indolent Non-Hodgkin Lymphoma

Advertisement

© 2021 HSP News Service, L.L.C.